期刊文献+

川芎嗪芳酸醚甘氨酸衍生物合成及抗血小板聚集活性 被引量:3

Synthesis of a series of glycine derivatives ligustrazine-aromatic acid and their inhibitory effects on platelet aggregation
暂未订购
导出
摘要 目的合成一系列新的甘氨酸衍生物,并初步筛选其抗血小板聚集活性。方法以川芎嗪、甘氨酸、阿魏酸等芳酸为起始原料,经过一系列反应,合成得到目标化合物。结果合成了6个川芎嗪芳酸醚类甘氨酸衍生物,其结构均经IR、1H-NMR、13C-NMR和MS确证。结论所有目标化合物均未见文献报道。药理结果初步显示化合物1a、1b、1c、1d、1e、1f血小板抑制率分别为8.2%、6.5%、15.9%、6.7%、5.1%、3.2%。 Aim To synthesize a series of new glycine derivatives and to study their inhibitory effects on platelet aggregation.Methods The target compounds were synthesized from Ligustrazine,glycine,ferulic acid and its analogs via a series of reactions.Results Six target compounds were synthesized.Their structures were characterized by IR,1H-NMR,13C-NMR and MS.Conclusions The target compounds have not been reported in literatures.Preliminary pharmacological results show that the inhibitory effect on platelet aggregation of compounds 1a,1b,1c,1d,1e,1f is 8.2%,6.5%,15.9%,6.7%,5.1%,and 3.2%.
出处 《安徽医药》 CAS 2011年第8期937-940,共4页 Anhui Medical and Pharmaceutical Journal
基金 国家科技重大专项重大新药创制项目(批准号:2009ZX09103-123) 安徽省高校自然基金重点项目(批准号:KJ2010A206)
关键词 川芎嗪 甘氨酸 抗血小板聚集 化学合成 ligustrazine glycine platelet aggregation inhibitory synthesis
  • 相关文献

参考文献10

二级参考文献131

共引文献111

同被引文献22

  • 1周远鹏,刘文化,邵国贤.益母草碱、丁香酰胍醇及丁香酸氨基醇酯类化合物抗血小板聚集活性及其与结构的关系[J].中国药学杂志,1996,31(5):271-274. 被引量:19
  • 2Loh K P,Qi J,Tan BKH. Leonruine protects middle artery occluded rats through antioxidant effect and regulation of mitochondrial function[J].Stroke,2010,(11):2661-2668.
  • 3Hang CL,Sheng MP,Hsiou YD. Anti-platelet Effect of Leonurine from Leonurus sibiricus[J].J Taiwan Pharmaceutical,2007.149-152.
  • 4Loh KP,Huang SH,Tan BKH. Cerebral protection of purified Herba Leonuri extract on middle cerebral artery occluded rats[J].Journal of Ethnopharmacology,2009,(02):337-343.doi:10.1016/j.jep.2009.05.025.
  • 5Kim JH,Yenari MA,Giffard RG. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects culture neurons from ischemia-like injury[J].Experimental Neurology,2004.122-130.
  • 6Hasson H,Galli L,Gallotta G. HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment:a randomised pilot study(KaMon)[J].{H}New Microbiologica,2012,(04):469-474.
  • 7Cooper C,la-Porte C,Tossonian H. A pilot,prospective,open-label simplification study to evaluate the safety,efficacy,and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients:the MONOCO study[J].{H}HIV CLINICAL TRIALS,2012,(04):179-188.
  • 8Lambert-Niclot S,Masquelier B,Cohen Codar I. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice[J].{H}Journal of Antimicrobial Chemotherapy,2012,(10):2487-2493.
  • 9Josephson F,Andersson MC,Flamholc L. The relation between treatment outcome and efavirenz,atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients[J].{H}EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,2010,(04):349-357.
  • 10何勇;陈仕云;余三喜.利托那韦异构体杂质的合成研究及控制方法[P]中国:102786494,2012.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部